Abstract
NF-κB proteins play a central and subunit-specific role in the response to DNA damage. Previous work identified p50/NF-κB1 as being necessary for cytotoxicity in response to DNA alkylation damage. Given the importance of damage-induced cell death for the maintenance of genomic stability, we examined whether Nfkb1 acts as a tumor suppressor in the setting of alkylation damage. Hprt mutation analysis demonstrates that Nfkb1−/− cells accumulate more alkylator-induced, but not ionizing radiation (IR)-induced, mutations than similarly treated wild-type cells. Subsequent in vivo tumor induction studies reveal that following alkylator treatment, but not IR, Nfkb1−/− mice develop more lymphomas than similarly treated Nfkb1+/+ animals. Heterozygous mice develop lymphomas at an intermediate rate and retain functional p50 in their tumors, indicating that Nfkb1 acts in a haploinsufficient manner. Analysis of human cancers, including therapy-related myeloid neoplasms, demonstrates that NFKB1 mRNA expression is downregulated compared with control samples in multiple hematological malignancies. These data indicate that Nfkb1 is a haploinsufficient, pathway-specific tumor suppressor that prevents the development of hematologic malignancy in the setting of alkylation damage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Allan JM, Travis LB . Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005; 5: 943–955.
Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43–52.
Rayet B, Gelinas C . Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938–6947.
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285–296.
Perkins ND . NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004; 14: 64–69.
Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421: 639–643.
Ryan KM, Ernst MK, Rice NR, Vousden KH . Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000; 404: 892–897.
Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND . Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. Embo J 2005; 24: 1157–1169.
Wolff B, Naumann M . INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaB. Oncogene 1999; 18: 2663–2666.
Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W et al. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 2006; 25: 6781–6799.
Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS et al. p50 (NF-kappaB1) is an effector protein in the cytotoxic response to DNA methylation damage. Mol Cell 2011; 44: 785–796.
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C . Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35–61.
Margison GP, Santibanez Koref MF, Povey AC . Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002; 17: 483–487.
Joshi VV, Frei JV . Effects of dose and schedule of methylnitrosourea on incidence of malignant lymphoma in adult female mice. J Natl Cancer Inst 1970; 45: 335–339.
Dumenco LL, Allay E, Norton K, Gerson SL . The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science 1993; 259: 219–222.
Sha WC, Liou HC, Tuomanen EI, Baltimore D . Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995; 80: 321–330.
Hoffmann A, Leung TH, Baltimore D . Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. Embo J 2003; 22: 5530–5539.
Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007; 117: 823–834.
Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198–1203.
Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937–3949.
Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.
Glauert HP, Eyigor A, Tharappel JC, Cooper S, Lee EY, Spear BT . Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-kappaB in mice administered the peroxisome proliferator Wy-14,643. Toxicol Sci 2006; 90: 331–336.
Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R . Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665–677.
Chang PY, Draheim K, Kelliher MA, Miyamoto S . NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Res 2006; 66: 6008–6013.
Li Z, Wang X, Yu RY, Ding BB, Yu JJ, Dai XM et al. BCL-6 negatively regulates expression of the NF-kappaB1 p105/p50 subunit. J Immunol 2005; 174: 205–214.
Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL . Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene 2005; 24: 6231–6240.
Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35–45.
Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB . Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012; 30: 3734–3745.
Neyns B, Cordera S, Joosens E, Pouratian N . Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide. J Clin Oncol 2008; 26: 4518–4519.
Kinzler KW, Vogelstein B . Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386: 763.
Sherr CJ . Principles of tumor suppression. Cell 2004; 116: 235–246.
Yamini B, Yu X, Dolan ME, Wu MH, Darga TE, Kufe DW et al. Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res 2007; 67: 6889–6898.
Olive PL, Banath JP . The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006; 1: 23–29.
McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 2013; 121: 975–983.
Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, Kim IF et al. NCBI GEO: archive for functional genomics data sets–10 years on. Nucleic Acids Res 2011; 39: D1005–D1010.
Davis S, Meltzer PS . GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 2007; 23: 1846–1847.
Du P, Kibbe WA, Lin SM . lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547–1548.
Acknowledgements
We are grateful to RF de Pooter and B Kee for helpful contributions. This work was supported by NIH grant 1R01CA136937 (to BY), The Ludwig Center for Metastasis Research; Leukemia & Lymphoma Society Fellow award (M.E.M) and the Chicago Cancer Genomes Project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Voce, D., Schmitt, A., Uppal, A. et al. Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor. Oncogene 34, 2807–2813 (2015). https://doi.org/10.1038/onc.2014.211
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2014.211
This article is cited by
-
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Molecular and Cellular Pediatrics (2023)
-
Unraveling the molecular mechanism of l-menthol against cervical cancer based on network pharmacology, molecular docking and in vitro analysis
Molecular Diversity (2023)
-
p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability
Nature Communications (2020)
-
Role of the ubiquitin ligase KPC1 in NF-κB activation and tumor suppression
Journal of Analytical Science and Technology (2016)